A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

Inclusion Criteria: * Aged 18 to 60 years and no gender limit (including 18 and 60 years). * HBsAg positive for more than 6 months. * Patients with intermediate to high liver cancer risks. Refers to if at least one of the following items is met. * Male patient aged above 40 years. * Patients with a history of cirrhosis and/or family history of liver cancer. * Patients with metabolic diseases, such as diabetes, fatty liver, etc. * Any liver cancer assessment model of chronic hepatitis B patients suggested that liver cancer was at intermediate to high risk. * Have received Nucleos(t)ide analogue treatment for more than 24 weeks, and currently receiving Nucleos(t)ide analogue, while HBV DNA is undetectable (HBV DNA below 300 IU/mL or 1000 copies/mL). * Urine and/or serum pregnancy test within 24 hours prior to the first dose must be negative for female patients of childbearing potential. * Understand and voluntarily sign informed consent form. Exclusion Criteria: * Patients co-infected with active hepatitis A, hepatitis C, hepatitis D, hepatitis E or HIV. * Patients who have previously received interferon therapy. * Alpha-fetoprotein greater than 100 ng/mL at screening, or liver imaging suggestive of liver tumor. * Decompensated liver disease (Child-Pugh score ≥ 5). * Pregnant or lactating women or patients planning to become pregnant or cannot to take contraception during the study. * Neutrophil count \< 1.5 x 109/L, platelet count \< 90 x 109 cells/L, or Creatinine 1.5 times higher than the upper limit of normal. * Patients with severe psychiatric history, particularly depression. * History of immune-mediated disease or levels of autoimmune antibodies markedly elevated. * Patients with severe diseases in major organ, such as heart, lung, kidney, brain, blood, etc., and patients with malignancies. * Patients with poorly controlled diabetes, hypertension, and thyroid disease. * Patients with history of severe retinopathy or other evidence of retinopathy. * Patient who ever received organ transplantation, or planning to receive organ transplantation. * Patients who are allergic to interferon or any of its ingredients. * Other circumstances that the investigator deems inappropriate to participate in this study.